Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a common form of non-Hodgkin lymphoma, saying that the phase 2 trial data is compelling enough to file with regulators later this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,